Spots Global Cancer Trial Database for brca1 mutation carrier
Every month we try and update this database with for brca1 mutation carrier cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | NCT01154426 | Adult Solid Neo... BRCA1 Mutation ... BRCA2 Mutation ... | Diagnostic Labo... Gemcitabine Hyd... Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT01233505 | Adenocarcinoma ... Adenocarcinoma ... BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Mucinou... Recurrent Breas... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Colon ... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Unspecified Adu... | veliparib capecitabine oxaliplatin pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer | NCT01874184 | Atypical Ductal... Atypical Lobula... BRCA1 Mutation ... BRCA2 Mutation ... Ductal Breast C... Lobular Breast ... | counseling inte... behavioral diet... exercise interv... questionnaire a... laboratory biom... | 35 Years - 65 Years | University of Washington | |
| Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy | NCT00084370 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | celecoxib oophorectomy | 19 Years - | University of Alabama at Birmingham | |
| Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01540565 | BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Epithel... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Laboratory Biom... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy | NCT00084370 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | celecoxib oophorectomy | 19 Years - | University of Alabama at Birmingham | |
| Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers | NCT00899145 | BRCA1 Mutation ... BRCA2 Mutation ... Breast Carcinom... | Laboratory Biom... | 18 Years - 80 Years | GOG Foundation | |
| Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy | NCT00084370 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | celecoxib oophorectomy | 19 Years - | University of Alabama at Birmingham | |
| Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | NCT01905046 | Atypical Ductal... BRCA1 Mutation ... BRCA2 Mutation ... Ductal Breast C... Lobular Breast ... | metformin hydro... placebo | 25 Years - 55 Years | Alliance for Clinical Trials in Oncology | |
| 3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women | NCT01409226 | Breast Cancer BRCA1 Mutation BRCA2 Mutation | 3.0-T MRI biopsy | 18 Years - 70 Years | NYU Langone Health | |
| Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations | NCT00700778 | BRCA1 Mutation Breast Cancer | recombinant hum... microarray anal... immunohistochem... laboratory biom... needle biopsy | 20 Years - 40 Years | Fox Chase Cancer Center | |
| Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries | NCT00098800 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | fenretinide | 30 Years - | University of Arizona | |
| Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | NCT00535119 | Adult Solid Neo... BRCA1 Mutation ... BRCA2 Mutation ... Hereditary Brea... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer | NCT01219075 | BRCA1 Mutation ... BRCA2 Mutation ... Ductal Breast C... Lobular Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... | soy isoflavones placebo questionnaire a... magnetic resona... biopsy immunohistochem... laboratory biom... mammography | 30 Years - 75 Years | University of Southern California | |
| Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | NCT01506609 | Metastatic Brea... | Placebo Veliparib Carboplatin Temozolomide Paclitaxel | 18 Years - | AbbVie | |
| Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer | NCT00986206 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | Biomarker LPA a... | 18 Years - 95 Years | Women and Infants Hospital of Rhode Island | |
| Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations | NCT00700778 | BRCA1 Mutation Breast Cancer | recombinant hum... microarray anal... immunohistochem... laboratory biom... needle biopsy | 20 Years - 40 Years | Fox Chase Cancer Center | |
| S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer | NCT01097278 | brca1 Mutation ... brca2 Mutation ... Breast Cancer | cholecalciferol placebo | 18 Years - 50 Years | SWOG Cancer Research Network | |
| Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | NCT01905046 | Atypical Ductal... BRCA1 Mutation ... BRCA2 Mutation ... Ductal Breast C... Lobular Breast ... | metformin hydro... placebo | 25 Years - 55 Years | Alliance for Clinical Trials in Oncology | |
| Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | NCT01905046 | Atypical Ductal... BRCA1 Mutation ... BRCA2 Mutation ... Ductal Breast C... Lobular Breast ... | metformin hydro... placebo | 25 Years - 55 Years | Alliance for Clinical Trials in Oncology | |
| Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer | NCT00986206 | brca1 Mutation ... brca2 Mutation ... Ovarian Cancer | Biomarker LPA a... | 18 Years - 95 Years | Women and Infants Hospital of Rhode Island | |
| Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease | NCT00080756 | brca1 Mutation ... brca2 Mutation ... Breast Cancer | therapeutic est... deslorelin therapeutic tes... therapeutic con... active surveill... quality-of-life... laboratory biom... | 21 Years - 48 Years | City of Hope Medical Center | |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT01233505 | Adenocarcinoma ... Adenocarcinoma ... BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Mucinou... Recurrent Breas... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Colon ... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Unspecified Adu... | veliparib capecitabine oxaliplatin pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | NCT02314156 | BRCA1 Mutation ... BRCA2 Mutation ... Ductal Breast C... Lobular Breast ... Stage 0 Breast ... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... | Telapristone Ac... Placebo Telapristone Ac... Placebo Laboratory Biom... Questionnaire A... | 18 Years - | Northwestern University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
